244.32
price down icon0.34%   -0.84
after-market 시간 외 거래: 244.32
loading
전일 마감가:
$245.16
열려 있는:
$239.25
하루 거래량:
353.16K
Relative Volume:
0.83
시가총액:
$28.51B
수익:
$3.81B
순이익/손실:
$-644.79M
주가수익비율:
-39.15
EPS:
-6.24
순현금흐름:
$-669.77M
1주 성능:
-8.54%
1개월 성능:
-0.65%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
Value
$239.25
$244.65
1주일 범위
Value
$239.25
$266.32
52주 변동 폭
Value
$172.67
$287.88

Beone Medicines Ltd Adr Stock (ONC) Company Profile

Name
명칭
Beone Medicines Ltd Adr
Name
전화
13459494123
Name
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
직원
11,000
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ONC's Discussions on Twitter

ONC을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33

Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-07 개시 RBC Capital Mkts Outperform
2025-03-03 업그레이드 BofA Securities Neutral → Buy
2024-12-03 재개 Morgan Stanley Overweight
2024-09-18 개시 JMP Securities Mkt Outperform
2024-02-06 재개 JP Morgan Overweight
2023-09-12 개시 Macquarie Outperform
2023-08-17 개시 Jefferies Buy
2023-07-17 개시 Citigroup Buy
2023-06-30 다운그레이드 Bernstein Outperform → Mkt Perform
2023-01-12 개시 Daiwa Securities Buy
2022-10-13 업그레이드 Guggenheim Neutral → Buy
2022-10-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2022-08-09 재개 JP Morgan Overweight
2022-03-17 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-02-07 개시 Deutsche Bank Buy
2021-10-12 개시 Bernstein Outperform
2021-10-06 업그레이드 CLSA Underperform → Buy
2021-03-08 개시 China Renaissance Buy
2021-03-01 다운그레이드 CLSA Outperform → Underperform
2020-11-09 다운그레이드 Ladenburg Thalmann Buy → Neutral
2020-11-06 다운그레이드 Maxim Group Buy → Hold
2020-11-06 다운그레이드 Piper Sandler Neutral → Underweight
모두보기

Beone Medicines Ltd Adr 주식(ONC)의 최신 뉴스

pulisher
Jun 18, 2025

Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 1,543 Shares of Stock - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Insider Sells $118,143.90 in Stock - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat

Jun 16, 2025
pulisher
Jun 13, 2025

Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jun 13, 2025
pulisher
Jun 05, 2025

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily

Jun 05, 2025
pulisher
Jun 03, 2025

LLY Stock Quote Price and Forecast - CNN

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India

Jun 02, 2025
pulisher
May 31, 2025

China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

China approves novel HER2-targeted therapy for BTC - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.

May 30, 2025
pulisher
May 27, 2025

BeiGene completes corporate re-domiciliation to Switzerland - Investing.com

May 27, 2025
pulisher
May 27, 2025

BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com Nigeria

May 27, 2025
pulisher
May 26, 2025

Daiwa Raises BEIGENE's TP to HKD180; Brukinsa Sales Growth Outpaces Competitors - AASTOCKS.com

May 26, 2025
pulisher
May 21, 2025

BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India

May 21, 2025
pulisher
May 13, 2025

Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com

May 13, 2025
pulisher
May 08, 2025

Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX

May 08, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com

May 07, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

Universal Health Q1 Earnings Beat on Strong Acute Care Admissions - Zacks Investment Research

Apr 29, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 21, 2025

BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com

Apr 21, 2025
pulisher
Apr 17, 2025

BGNE Page Not Found - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 10, 2025

Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com

Apr 10, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com

Apr 07, 2025
pulisher
Apr 04, 2025

JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha

Apr 03, 2025
pulisher
Mar 31, 2025

Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com

Mar 31, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com

Mar 18, 2025

Beone Medicines Ltd Adr (ONC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Beone Medicines Ltd Adr 주식 (ONC) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Wu Xiaobin
President and COO
Jun 23 '25
Sale
260.00
1,363
354,380
0
Wang Xiaodong
Chair, Scientific Advisory Brd
Jun 24 '25
Sale
265.50
2,007
532,867
0
OYLER JOHN
Chief Executive Officer
Jun 23 '25
Sale
261.61
3,174
830,360
0
$108.26
price up icon 0.70%
$545.11
price up icon 0.49%
$329.77
price up icon 2.39%
$98.24
price up icon 0.64%
$22.62
price up icon 6.70%
자본화:     |  볼륨(24시간):